MedTrace Logo

Study of Nicotine Patches in Patients With Sarcoidosis

NCT00701207 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-11-08

No results posted yet for this study

Summary

The purpose of this study is to compare peoples with disease (sarcoidosis) to those without disease. We want to see if people with sarcoidosis have a different immune response to those people without disease.

The goal of this study is to see if the nicotine patch is an anti-inflammatory treatment for sarcoidosis.

Conditions

  • Pulmonary Sarcoidosis

Interventions

DRUG

nicotine patch

daily transdermal patch 7 mg, 14mg, 21 mg. 3 months

Sponsors & Collaborators

  • American Thoracic Society

    collaborator OTHER

  • Elliott Crouser MD

    lead OTHER

Principal Investigators

  • Elliott D. Crouser, M.D. · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701207 on ClinicalTrials.gov